Dizal (jiangsu) Pharmaceutical Co. Ltd. Class ASSE: 688192

"DIZAL PHARMACEUTICAL CO., LTD."Announcement on Voluntary Disclosure of Publication of Research Results on Birelentinib for the Treatment of Diffuse Large B-Cell Lymphoma in "Blood Cancer Journal"

Sep 10, 2026 · Issued by Dizal (jiangsu) Pharmaceutical Co. Ltd. Class A via Shanghai Stock Exchange

Filed with SSE · Sep 10, 2026

Announcement on Voluntary Disclosure of Publication of Research Results on Birelentinib for the Treatment of Diffuse Large B-Cell Lymphoma in "Blood Cancer Journal"

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

6ix hasn’t read this filing yet.

Company analysis

Earlier from Dizal (jiangsu) Pharmaceutical Co. Ltd. Class A

"DIZAL PHARMACEUTICAL CO., LTD."Announcement on Participating in the 2026 Semi-annual Collective Performance Briefing for the Innovative Drug IndustrySep 9
"DIZAL PHARMACEUTICAL CO., LTD."Announcement on Shareholding Reduction Plan of Directors and Senior ManagementSep 4
"DIZAL PHARMACEUTICAL CO., LTD."Announcement on Voluntary Disclosure of the Acceptance by the U.S. FDA of the Supplemental New Drug Application for Sunvozertinib as a Monotherapy for the First-Line Treatment of Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion MutationsAug 31
Dizal to Present Emerging Data on ZEGFROVY® in Non-Small Cell Lung Cancer at WCLC 2026Aug 21

All Dizal (jiangsu) Pharmaceutical Co. Ltd. Class A news releases